Drug |
Pharmacologic Class |
Indication |
More Information |
Dermatological Disorders | |||
Olumiant (baricitinib) | Janus kinase inhibitor | Treatment of adults with severe alopecia areata. | Olumiant Drug Monograph |
Gastrohepatic Disorders | |||
Skyrizi (risankizumab-rzaa) | Interleukin-23 antagonist | Treatment of moderately to severely active Crohn disease in adults. | Skyrizi Approved for Moderately to Severely Active Crohn Disease |
Immunization | |||
Priorix (measles, mumps rubella vaccine, live) | Measles, Mumps Rubella Vaccine, Live | For active immunization for the prevention of measles, mumps and rubella in individuals 12 months of age and older. | FDA Approves Additional Option for Measles, Mumps and Rubella Vaccination |
Oncology | |||
Breyanzi (lisocabtagene maraleucel) |
CD19-directed genetically modified autologous T cell immunotherapy.
|
Treatment of adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation due to comorbidities or age. | Breyanzi Drug Monograph |
Tafinlar + Mekinist (dabrafenib + trametinib) | Kinase inhibitor | Treatment of individuals 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation, who have progressed following prior treatment and have no satisfactory alternative treatment options. | Tafinlar-Mekinist Combo Wins Tumor-Agnostic Indication for BRAF V600E Solid Tumors |
Rare Diseases | |||
Amvuttra (vutrisiran) |
Chemically modified double-stranded small interfering ribonucleic acid that targets mutant and wild-type transthyretin messenger RNA |
Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. | Amvuttra Approved for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis |
Imcivree (setmelanotide) | Melanocortin receptor agonist | Treatment of chronic weight management in patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome. | Imcivree Drug Monograph |
Publish Date